Esperion Therapeutics Ne (ESPR) Shareholder Parallax Volatility Advisers LP Has Cut Its Position by $73.01 Million as Stock Rose; Pfizer Com (PFE) Holder Nelson Van Denburg & Campbell Wealth Management Group Has Cut Holding

February 15, 2018 - By Ellis Scott

Parallax Volatility Advisers Lp decreased its stake in Esperion Therapeutics Inc Ne (ESPR) by 99.29% based on its latest 2017Q3 regulatory filing with the SEC. Parallax Volatility Advisers Lp sold 1.46 million shares as the company’s stock rose 33.24% with the market. The institutional investor held 10,469 shares of the health care company at the end of 2017Q3, valued at $525,000, down from 1.47 million at the end of the previous reported quarter. Parallax Volatility Advisers Lp who had been investing in Esperion Therapeutics Inc Ne for a number of months, seems to be less bullish one the $1.95 billion market cap company. The stock increased 0.79% or $0.58 during the last trading session, reaching $74.34. About 215,586 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 15, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Nelson Van Denburg & Campbell Wealth Management Group Llc decreased its stake in Pfizer Inc Com (PFE) by 14.97% based on its latest 2017Q3 regulatory filing with the SEC. Nelson Van Denburg & Campbell Wealth Management Group Llc sold 7,979 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 45,313 shares of the health care company at the end of 2017Q3, valued at $1.94M, down from 53,292 at the end of the previous reported quarter. Nelson Van Denburg & Campbell Wealth Management Group Llc who had been investing in Pfizer Inc Com for a number of months, seems to be less bullish one the $211.52B market cap company. The stock increased 0.84% or $0.295 during the last trading session, reaching $35.485. About 10.76 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since February 15, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Since August 21, 2017, it had 0 buys, and 8 sales for $12.56 million activity. 7,350 shares valued at $249,900 were sold by MACKENZIE ALEXANDER R on Thursday, August 31. JOHNSON RADY A had sold 8,000 shares worth $296,560 on Friday, December 15. 38,230 shares were sold by SUSMAN SALLY, worth $1.34M. DAMELIO FRANK A also sold $3.21M worth of Pfizer Inc. (NYSE:PFE) on Thursday, August 31. OLSON LAURIE J sold $263,693 worth of stock or 8,064 shares.

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer had 74 analyst reports since July 29, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, October 28 report. Piper Jaffray maintained it with “Buy” rating and $54.0 target in Thursday, September 14 report. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Monday, October 16. Jefferies has “Hold” rating and $38.0 target. The stock of Pfizer Inc. (NYSE:PFE) has “Neutral” rating given on Wednesday, November 25 by Suntrust Robinson. Jefferies maintained Pfizer Inc. (NYSE:PFE) on Thursday, April 7 with “Buy” rating. The rating was maintained by Piper Jaffray on Friday, August 14 with “Buy”. The firm has “Sell” rating given on Tuesday, May 16 by Citigroup. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, November 21. The company was upgraded on Tuesday, October 20 by Cowen & Co. The firm has “Market Perform” rating given on Wednesday, November 2 by BMO Capital Markets.

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It increased, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Wealthcare Cap Llc invested 0% of its portfolio in Pfizer Inc. (NYSE:PFE). Bryn Mawr Tru owns 282,521 shares for 0.57% of their portfolio. Burke And Herbert State Bank And Trust accumulated 64,744 shares. Northstar Investment Advisors Ltd holds 17,379 shares. The Delaware-based Reliance Of Delaware has invested 0.53% in Pfizer Inc. (NYSE:PFE). The Missouri-based Shelter Insurance Retirement Plan has invested 1.89% in Pfizer Inc. (NYSE:PFE). First Personal Finance Services has invested 1.16% in Pfizer Inc. (NYSE:PFE). Peoples Corp owns 119,680 shares for 2.42% of their portfolio. First Bank Of Mount Dora Trust Inv Services has invested 2.4% in Pfizer Inc. (NYSE:PFE). Welch Lc accumulated 7,572 shares or 0.05% of the stock. Btr Capital owns 1.86% invested in Pfizer Inc. (NYSE:PFE) for 256,060 shares. Wolverine Asset Management Limited Co stated it has 95,149 shares or 0.04% of all its holdings. Evanson Asset Mgmt Limited Liability reported 0.12% stake. Horrell Incorporated accumulated 0% or 159 shares. Wealthfront invested 0.07% of its portfolio in Pfizer Inc. (NYSE:PFE).

Nelson Van Denburg & Campbell Wealth Management Group Llc, which manages about $183.81M and $304.07M US Long portfolio, upped its stake in Walgreens Boots Alliance Inc Com by 182,377 shares to 202,254 shares, valued at $1.57M in 2017Q3, according to the filing. It also increased its holding in Ishares Core S&P 500 Etf (IVV) by 1,415 shares in the quarter, for a total of 9,076 shares, and has risen its stake in Vanguard Value Index Fund (VTV).

Investors sentiment increased to 1.67 in 2017 Q3. Its up 0.45, from 1.22 in 2017Q2. It is positive, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Metropolitan Life Ins New York holds 10,896 shares. Dimensional Fund Advisors LP has 90,750 shares for 0% of their portfolio. New York State Common Retirement Fund, New York-based fund reported 15,900 shares. Voya Inv Ltd Liability reported 0% stake. Meeder Asset Mngmt Incorporated reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Alliancebernstein LP invested in 0% or 24,970 shares. Credit Suisse Ag invested in 1.06M shares. Ubs Asset Mgmt Americas Inc invested in 39,898 shares. Wellington Mgmt Gp Ltd Liability Partnership reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Vanguard Gp has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 880,323 shares. Jane Street Grp Ltd accumulated 11,247 shares or 0% of the stock. Lord Abbett Limited Liability reported 235,889 shares. Morgan Stanley reported 33,212 shares. State Of New Jersey Common Pension Fund D stated it has 36,875 shares. Ameritas Investment Ptnrs Incorporated owns 1,310 shares for 0% of their portfolio.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Friday, November 6. The rating was downgraded by JP Morgan on Wednesday, June 29 to “Neutral”. On Friday, August 7 the stock rating was maintained by Chardan Capital Markets with “Sell”. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 15 report. Bank of America upgraded the shares of ESPR in report on Friday, January 5 to “Buy” rating. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, November 22 by Northland Capital. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Sector Perform” rating by RBC Capital Markets on Thursday, February 23. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Underperform” rating by Credit Suisse on Wednesday, June 29. On Wednesday, June 29 the stock rating was maintained by Citigroup with “Buy”. Jefferies upgraded Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Wednesday, August 9 to “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts